A better understanding of the role of PAR-1 in the inflammatory response in COVID-19 patients with T2DM, and drugs targeting PAR-1 or its downstream signaling pathways, could be potential novel therapeutic targets to mitigate inflammation and improve outcomes in these patients. This evidence concerns the gene F2R and type 2 diabetes mellitus.